Dementia

Identifying dementia with Lewy bodies in the presence of Alzheimer’s disease

Performance of plasma p-tau181 as a community-based screening tool for AD clinical trials

Associations between predicted brain age and Alzheimer’s Disease biomarkers

Lipidomics as a tool for dementia research

Can biomarkers help to predict brain age?

Nilotinib: a potential repurposed treatment for Alzheimer’s disease?

The diagnostic and prognostic performance of U-p53AZ as a blood-based biomarker for AD

Personalized approach to dementia prevention and treatment

Can the APOEε4 genotype contribute to tau pathology progression?

The Phase III NILEAD trial: nilotinib as a novel treatment for AD

The value of plasma p-tau181 as a screening and diagnostic tool for Alzheimer’s disease

The future of SAGE-718 in Alzheimer’s disease treatment

Understanding the effect of other diseases on blood biomarker levels in AD

The impact of TKIs on miRNA expression in the treatment of AD

Use of machine learning in Alzheimer’s disease

Implementing novel clinical trial designs for dementia with Lewy bodies